Teachers Retirement System of The State of Kentucky Has $751,000 Stake in Charles River Laboratories International, Inc. (NYSE:CRL)

Teachers Retirement System of The State of Kentucky reduced its stake in Charles River Laboratories International, Inc. (NYSE:CRL) by 8.7% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,814 shares of the medical research company’s stock after selling 363 shares during the period. Teachers Retirement System of The State of Kentucky’s holdings in Charles River Laboratories International were worth $751,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Toronto Dominion Bank grew its stake in shares of Charles River Laboratories International by 1.6% during the third quarter. Toronto Dominion Bank now owns 25,617 shares of the medical research company’s stock worth $5,046,000 after buying an additional 397 shares during the last quarter. Neo Ivy Capital Management acquired a new stake in shares of Charles River Laboratories International during the 3rd quarter valued at $966,000. Gould Capital LLC bought a new stake in Charles River Laboratories International during the 3rd quarter worth $1,225,000. M&T Bank Corp increased its holdings in Charles River Laboratories International by 3.4% in the 3rd quarter. M&T Bank Corp now owns 2,001 shares of the medical research company’s stock worth $394,000 after purchasing an additional 66 shares in the last quarter. Finally, Nomura Asset Management Co. Ltd. raised its position in Charles River Laboratories International by 13.7% in the third quarter. Nomura Asset Management Co. Ltd. now owns 15,592 shares of the medical research company’s stock valued at $3,071,000 after purchasing an additional 1,882 shares during the last quarter. 98.91% of the stock is owned by institutional investors.

Charles River Laboratories International Stock Down 3.3 %

Shares of NYSE:CRL opened at $183.16 on Thursday. Charles River Laboratories International, Inc. has a 1 year low of $176.48 and a 1 year high of $275.00. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.48 and a quick ratio of 1.14. The business’s 50-day moving average is $194.33 and its 200-day moving average is $202.55. The company has a market capitalization of $9.37 billion, a price-to-earnings ratio of 22.92, a P/E/G ratio of 5.00 and a beta of 1.38.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings results on Wednesday, November 6th. The medical research company reported $2.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.43 by $0.16. The firm had revenue of $1.01 billion for the quarter, compared to analyst estimates of $975.99 million. Charles River Laboratories International had a return on equity of 14.29% and a net margin of 10.44%. The company’s revenue was down 1.6% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.72 earnings per share. Equities research analysts predict that Charles River Laboratories International, Inc. will post 10.18 earnings per share for the current year.

Analysts Set New Price Targets

Several analysts have recently weighed in on CRL shares. UBS Group boosted their price target on Charles River Laboratories International from $240.00 to $250.00 and gave the stock a “buy” rating in a report on Thursday, November 7th. Bank of America reduced their target price on shares of Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating on the stock in a report on Friday, December 13th. CLSA downgraded shares of Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 price target for the company. in a research note on Monday, November 18th. TD Cowen boosted their price objective on shares of Charles River Laboratories International from $203.00 to $227.00 and gave the stock a “hold” rating in a research note on Monday, November 11th. Finally, Redburn Atlantic initiated coverage on Charles River Laboratories International in a research report on Monday, October 14th. They set a “sell” rating and a $151.00 target price for the company. Three investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $214.00.

Insider Activity at Charles River Laboratories International

In other Charles River Laboratories International news, Director Richard F. Wallman sold 6,621 shares of Charles River Laboratories International stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $216.12, for a total value of $1,430,930.52. Following the completion of the sale, the director now directly owns 12,386 shares of the company’s stock, valued at approximately $2,676,862.32. The trade was a 34.83 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 1.30% of the stock is owned by corporate insiders.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).